Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (ProQuad) [MMR-varicella zoster virus vaccine] and a booster dose of Infanrix hexa [Hib-DTaP-hepatitis B-poliovirus vaccine] in healthy children 12 to 23 months of age

Trial Profile

An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (ProQuad) [MMR-varicella zoster virus vaccine] and a booster dose of Infanrix hexa [Hib-DTaP-hepatitis B-poliovirus vaccine] in healthy children 12 to 23 months of age

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa)
  • Indications Chickenpox; Diphtheria; Haemophilus infections; Hepatitis B; Measles; Mumps; Pertussis; Poliomyelitis; Rubella; Tetanus
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur MSD
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 08 Apr 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
    • 01 Jul 2008 The expected completion date for this trial is now 1 Mar 2008, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top